Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
309.00
-2.40 (-0.77%)
Last updated: Apr 3, 2025
HKG:6990 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,337 | 1,529 | 92.96 | 81.79 |
Short-Term Investments | 283.98 | 325.87 | - | - |
Trading Asset Securities | 1,448 | 633.71 | - | - |
Cash & Short-Term Investments | 3,069 | 2,488 | 92.96 | 81.79 |
Cash Growth | 23.33% | 2576.80% | 13.65% | - |
Accounts Receivable | 60.76 | 1.35 | 61.8 | 22.73 |
Other Receivables | 183.33 | 123.1 | 42.63 | 47.83 |
Receivables | 244.09 | 124.45 | 104.43 | 70.56 |
Inventory | 110.51 | 63.03 | 52.64 | 50.72 |
Prepaid Expenses | 2.09 | 35.65 | - | - |
Other Current Assets | 67.33 | 96.01 | 82.29 | 95.27 |
Total Current Assets | 3,493 | 2,807 | 332.32 | 298.34 |
Property, Plant & Equipment | 758.11 | 692.73 | 647.82 | 474.17 |
Other Intangible Assets | 2.58 | 1.34 | 3.18 | 0.49 |
Other Long-Term Assets | 14.51 | 8.2 | 9.83 | 39.97 |
Total Assets | 4,268 | 3,510 | 993.15 | 812.96 |
Accounts Payable | 291.29 | 404.38 | 327.46 | 325.28 |
Accrued Expenses | 156.34 | 133.77 | 86.61 | 44.72 |
Short-Term Debt | - | - | 2,891 | 2,388 |
Current Portion of Leases | 41.84 | 54.41 | 82.26 | 1.66 |
Current Income Taxes Payable | 5.46 | 3.73 | 2.7 | 2.52 |
Current Unearned Revenue | 312.38 | 510.69 | 163.98 | 109.04 |
Other Current Liabilities | 2.54 | 3.03 | 613.57 | 573.72 |
Total Current Liabilities | 809.84 | 1,110 | 4,167 | 3,445 |
Long-Term Leases | 84.91 | 5.51 | 41.29 | 1.25 |
Long-Term Unearned Revenue | 64.6 | 64.74 | 10.68 | 10.68 |
Total Liabilities | 959.34 | 1,180 | 4,219 | 3,457 |
Common Stock | 227.27 | 219.2 | 107.37 | 107.37 |
Retained Earnings | -4,323 | -4,056 | -3,482 | -2,866 |
Comprehensive Income & Other | 7,404 | 6,167 | 148.63 | 114.83 |
Shareholders' Equity | 3,309 | 2,329 | -3,226 | -2,644 |
Total Liabilities & Equity | 4,268 | 3,510 | 993.15 | 812.96 |
Total Debt | 126.75 | 59.92 | 3,014 | 2,391 |
Net Cash (Debt) | 2,942 | 2,428 | -2,921 | -2,309 |
Net Cash Growth | 21.15% | - | - | - |
Net Cash Per Share | 13.27 | 13.22 | -30.58 | -24.98 |
Filing Date Shares Outstanding | 227.27 | 219.2 | 215.83 | 92.46 |
Total Common Shares Outstanding | 227.27 | 219.2 | 107.37 | 92.46 |
Working Capital | 2,683 | 1,697 | -3,835 | -3,147 |
Book Value Per Share | 14.56 | 10.63 | -30.05 | -28.60 |
Tangible Book Value | 3,306 | 2,328 | -3,229 | -2,644 |
Tangible Book Value Per Share | 14.55 | 10.62 | -30.08 | -28.60 |
Buildings | - | 294.4 | - | - |
Machinery | - | 262.26 | 221.56 | 200.16 |
Construction In Progress | - | 119.99 | 348.59 | 282.36 |
Leasehold Improvements | - | 14.45 | 13.67 | 0.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.